Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Brenzavvy discontinuation?
What is dabrafenib mesylate msn patent issue?
Generic brand for latisse?
Testosterone enanthate expiration?
Patent expiration date of guselkumab?

Trulicity market?

See the DrugPatentWatch profile for Trulicity

Trulicity (dulaglutide) – Market Snapshot (2024)

Item Detail
Manufacturer Eli Lilly & Co.
Indication Type 2 diabetes – once‑weekly subcutaneous injection; also approved in 2024 for chronic weight‑management under the brand “Trulicity W” (dulaglutide 1.2 mg).
Launch U.S. FDA approval: 2014 (30 µg/0.5 mL). Global roll‑out in 2015–2016.
Key Markets U.S., EU‑28, Canada, Japan, China, Brazil, Australia, UK, India, Southeast Asia.
Current Pricing (U.S.) $1,200–$1,300 per 1‑month vial (before insurance). Payer rebates and manufacturer copay programs can bring out‑of‑pocket costs down to $50–$150.
Sales 2023 U.S.: ~$3.0 B; 2023 global (Eli Lilly data): ~$4.8 B.
Year‑on‑year growth (YoY): 7.9 % in U.S., 6.3 % globally.
Market Share (U.S.) 18–20 % of the GLP‑1 RA segment (by revenue), ranking #2 behind Ozempic (semaglutide).
Competitive Landscape • Ozempic (semaglutide) – weekly, higher weight‑loss efficacy, slightly higher price.
• Victoza (liraglutide) – daily dosing, lower price.
• Byetta, Bydureon – older GLP‑1s, declining share.
• Emerging biosimilars (e.g., Bydureon‑biosimilar) – may erode market share if approved.
Key Trends Driving Growth 1. Weight‑loss indication – expanding Trulicity’s patient base beyond T2DM.
2. Digital health integration – “Trulicity Connect” app, dose‑tracking, and adherence analytics.
3. Payer value‑based contracts – rebates linked to HbA1c reduction and cardiovascular outcomes.
4. Global expansion – accelerated entry into India, Southeast Asia, and Africa driven by rising diabetes prevalence.
Pipeline & Future • Trulicity W (1.2 mg once‑weekly) FDA‑approved in 2024 for weight‑management.
• Combination product with tirzepatide (dual GLP‑1/GIP) in Phase 2.
Challenges • Reimbursement pressure – payers demand evidence of incremental benefit over cheaper GLP‑1s.
• Biosimilar competition – first GLP‑1 biosimilar launch expected Q3 2025.
• Supply chain disruptions – global raw‑material shortages may affect vial availability.

Quick Take

  • Trulicity remains a top‑tier GLP‑1 RA with solid U.S. and global sales, but it lags behind Ozempic in price‑per‑vial and weight‑loss efficacy.
  • Weight‑loss approval has broadened the patient pool, boosting revenue and offering a hedge against T2DM market saturation.
  • Digital tools and value‑based contracts are key to sustaining market share amid growing biosimilar threats.
  • Eli Lilly is positioning Trulicity as a “dual‑benefit” therapy—glycemic control + weight loss—while exploring combination therapies to stay ahead of next‑generation GLP‑1s like tirzepatide.

Want deeper numbers?

I can pull the latest quarterly earnings notes, detailed payer mix data, or projections for the 2025–2030 window. Just let me know what you need!



Other Questions About Trulicity :

What should i do if i miss a dose of trulicity? How does trulicity affect appetite over time? Cheaper substitute for trulicity? Does trulicity help weight? Maker of trulicity? Trulicity 4 5 mg price? Trulicity pen cost?